AGM/EGMJun 17, 2026, 04:57 PM
Annovis Bio Stockholders Approve All 5 Proposals at Annual Meeting
AI Summary
Annovis Bio, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 17, 2026, where all five proposals submitted to stockholders were approved. A total of 62.65% of the company's common stock was represented at the meeting. Key approvals included the election of five directors, the ratification of Ernst & Young LLP as independent auditors, and an amendment to the 2019 Equity Incentive Plan to increase the number of shares available for issuance.
Key Highlights
- Annovis Bio's 2026 Annual Meeting of Stockholders was held virtually with 62.65% of common stock outstanding represented.
- All five director nominees were elected to the Board for a one-year term.
- Stockholders ratified the appointment of Ernst & Young LLP as independent auditors with 20,634,176 votes For.
- The amendment to the 2019 Equity Incentive Plan, increasing shares to 5,500,000, was approved with 8,089,891 votes For.
- Stockholders approved the compensation of named executive officers on an advisory basis with 8,067,931 votes For.
- Stockholders preferred a two-year frequency for future advisory votes on executive compensation with 5,390,514 votes.
- The Company will include an advisory vote on executive compensation every two years.
Price Impact
More from ANVS